These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 27040707)

  • 1. Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia.
    Robak T; Blonski JZ; Robak P
    Semin Oncol; 2016 Apr; 43(2):280-90. PubMed ID: 27040707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.
    Robak T
    Expert Rev Hematol; 2014 Dec; 7(6):841-57. PubMed ID: 25249370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapies for CLL: Practical issues with the changing treatment paradigm.
    Jain N; O'Brien S
    Blood Rev; 2016 May; 30(3):233-44. PubMed ID: 26776345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target.
    Morabito F; Gentile M; Seymour JF; Polliack A
    Leuk Lymphoma; 2015; 56(12):3250-6. PubMed ID: 26062943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging immunological drugs for chronic lymphocytic leukemia.
    Robak P; Smolewski P; Robak T
    Expert Opin Emerg Drugs; 2015 Sep; 20(3):423-47. PubMed ID: 26153226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
    Hallek M
    Am J Hematol; 2015 May; 90(5):446-60. PubMed ID: 25908509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of Targeted Drugs to Control Chronic Lymphocytic Leukemia: Harnessing the Power of New Monoclonal Antibodies in Combination With Ibrutinib.
    Cramer P; Langerbeins P; Hallek M
    Cancer J; 2016; 22(1):62-6. PubMed ID: 26841018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chemotherapy-free treatment of chronic lymphocytic leukemia?].
    Wendtner CM
    Dtsch Med Wochenschr; 2013 Oct; 138(41):2104-6. PubMed ID: 24085367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.
    Robak T
    Future Oncol; 2013 Jan; 9(1):69-91. PubMed ID: 23252565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obinutuzumab for the treatment of chronic lymphocytic leukemia.
    Rogers KA; Jones JA
    Drugs Today (Barc); 2014 Jun; 50(6):407-19. PubMed ID: 24983589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status of monoclonal antibody therapy for chronic lymphocytic leukemia.
    Nabhan C; Dyer MJ; Rosen ST
    Oncology (Williston Park); 2003 Feb; 17(2):253-62; discussion 264, 267, passim. PubMed ID: 12632866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obinutuzumab for chronic lymphocytic leukemia.
    Rioufol C; Salles G
    Expert Rev Hematol; 2014 Oct; 7(5):533-43. PubMed ID: 25163491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.
    Jacobs RW; Awan FT; Leslie LA; Usmani SZ; Ghosh N
    Expert Rev Hematol; 2016 Dec; 9(12):1177-1187. PubMed ID: 27791448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.
    Wendtner CM; Gregor M
    Leuk Lymphoma; 2018 Feb; 59(2):300-310. PubMed ID: 28565930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of CD20 antibodies and kinase inhibitors on B-cell receptor signalling and survival of chronic lymphocytic leukaemia cells.
    Cavallini C; Galasso M; Pozza ED; Chignola R; Lovato O; Dando I; Romanelli MG; Krampera M; Pizzolo G; Donadelli M; Scupoli MT
    Br J Haematol; 2021 Jan; 192(2):333-342. PubMed ID: 33216963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Agents for the Frontline Management of Chronic Lymphocytic Leukemia.
    Burger JA
    Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 8):7-12. PubMed ID: 27168204
    [No Abstract]   [Full Text] [Related]  

  • 17. [Chronic lymphocytic leukemia: current standards and novel approaches].
    Tausch E; Stilgenbauer S
    Internist (Berl); 2014 Dec; 55(12):1400, 1402-4, 1406-9. PubMed ID: 25392275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ofatumumab for treating chronic lymphocytic leukemia: a safety profile.
    Korycka-Wołowiec A; Wołowiec D; Robak T
    Expert Opin Drug Saf; 2015; 14(12):1945-59. PubMed ID: 26566719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia.
    Robak T
    Curr Cancer Drug Targets; 2008 Mar; 8(2):156-71. PubMed ID: 18336199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.